BMS’ Opdivo and Yervoy Combination Fails to Meet Key Endpoint in Urothelial Cancer
Bristol Myers Squibb (BMS) said that its late-stage trial of Opdivo (nivolumab) plus Yervoy (ipilimumab) did not meet its goal of improving overall survival compared with standard-of-care treatment in certain…